Jared A. Head

Internal Medicine

2720 Sunset Blvd
West Columbia, SC 29169

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352].

Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352].

Journal: Bioorganic & medicinal chemistry letters

Published: April 28, 2022

Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors.

Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: July 15, 2021

Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity.

Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity.

Journal: ChemMedChem

Published: June 22, 2021

Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.

Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: February 07, 2021

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.

Journal: Journal of medicinal chemistry

Published: August 02, 2019

Discovery of Affinity-Based Probes for Btk Occupancy Assays.

Discovery of Affinity-Based Probes for Btk Occupancy Assays.

Journal: ChemMedChem

Published: November 07, 2018

Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.

Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: July 26, 2018

Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.

Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.

Journal: Bioorganic & medicinal chemistry letters

Published: June 04, 2018

Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.

Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.

Journal: Bioorganic & medicinal chemistry letters

Published: May 31, 2018

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: May 01, 2018

Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.

Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.

Journal: Molecular pharmacology

Published: September 25, 2016

Btk inhibition treats TLR7/IFN driven murine lupus.

Btk inhibition treats TLR7/IFN driven murine lupus.

Journal: Clinical immunology (Orlando, Fla.)

Published: December 18, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026